Cansera Inc.

Los Angeles, CA

UEI
KS4JGG27K1M6
CAGE
872R4
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1155 S Grand Ave, Los Angeles, CA 90015, USA
Website
cansera.com
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Health Care Equipment & Services
  3. Health Care Providers & Services
SIC code
80 Health Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

SBA capabilities narrative

Cansera, Inc. applies advanced technology to enhance cancer screening, monitoring, and treatment with the ultimate goal of improving patient outcomes. Our work centers on next-generation rare cell detection technologies powered by modern software architecture, machine learning, and AI-driven analytics. Our flagship platform, CellLogic, identifies and characterizes rare events from fluorescent whole slide imaging (fWSI) of human whole blood and other liquid biopsy samples, enabling highly scalable and clinically relevant insights.

Quick answers

Is Cansera Inc. registered in SAM.gov?

Yes. Cansera Inc.'s SAM.gov registration is active through September 8, 2027.

What is Cansera Inc.'s most recent federal award?

Cansera Inc.'s most recent federal contract award is Topic 425 - automated motion extraction and analysis to quantify patient performance status (75N91021C00051), from National Cancer Institute (NIH), on September 15, 2021.

On GovTribe

See Cansera Inc.'s full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors